Literature DB >> 8527469

Cognitive impairment and depression in the oldest old in a German and in U.S. communities.

M M Fichter1, M L Bruce, H Schröppel, I Meller, K Merikangas.   

Abstract

Data on cognitive impairment in the oldest old is reported comparing two different samples, one in Munich, Germany, and the other in the United States (Epidemiologic Catchment Area [ECA] study). In both studies the Mini Mental State Examination (MMSE) was used for assessing cognitive impairment. The Munich sample consisted of 402 and the ECA sample of 827 very old people aged 85 years and above. The results indicate that approximately 40% of each sample scored below 24 points in the MMSE indicating at least mild cognitive impairment. Severe cognitive impairment was found in 13.4% of the Munich and in 14.6% of the American sample. The prevalence of major depression was 1.4% in Munich and 2.0% in the ECA study, and dysthymia was found in 5.1% in the Munich and in 2.0% in the ECA sample aged 85 years and above. Persons living in institutions in both studies more frequently showed signs of cognitive impairment than those living in private households. The ECA sample, but not the Munich sample, showed a significantly higher prevalence of cognitive impairment for females and for the oldest age cohort above 90 years of age. Major depression was more frequent in Munich in persons living in institutions and in the ECA study among the oldest age cohort above 90 years of age. Dysthymia in both studies did not show any association with sociodemographic factors. Most of the excess comorbidity (cognitive impairment and depression) was observed among subjects with mild (and not with severe) cognitive impairment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 8527469     DOI: 10.1007/bf02191874

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  32 in total

Review 1.  Dementia and depression: an evolving enigma.

Authors:  J L Cummings
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1989       Impact factor: 2.198

2.  The prevalence of dementia in a total population: a comparison of two screening instruments.

Authors:  M Clarke; C Jagger; J Anderson; T Battcock; F Kelly; M C Stern
Journal:  Age Ageing       Date:  1991-11       Impact factor: 10.668

3.  A computerized psychiatric diagnostic system and case nomenclature for elderly subjects: GMS and AGECAT.

Authors:  J R Copeland; M E Dewey; H M Griffiths-Jones
Journal:  Psychol Med       Date:  1986-02       Impact factor: 7.723

4.  National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity.

Authors:  L N Robins; J E Helzer; J Croughan; K S Ratcliff
Journal:  Arch Gen Psychiatry       Date:  1981-04

5.  [Psychiatric disease in an elderly population. An epidemiologic field study in Mannheim].

Authors:  B Cooper; U Sosna
Journal:  Nervenarzt       Date:  1983-05       Impact factor: 1.214

6.  Mental and somatic health and need for care in octo- and nonagenerians. An epidemiological community study.

Authors:  I Meller; M Fichter; H Schröppel; M Beck-Eichinger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

7.  Prevalence of dementia in old age: clinical diagnoses in subjects aged 95 years and older.

Authors:  T F Wernicke; F M Reischies
Journal:  Neurology       Date:  1994-02       Impact factor: 9.910

8.  The Global Deterioration Scale for assessment of primary degenerative dementia.

Authors:  B Reisberg; S H Ferris; M J de Leon; T Crook
Journal:  Am J Psychiatry       Date:  1982-09       Impact factor: 18.112

9.  Pathological verification of ischemic score in differentiation of dementias.

Authors:  W G Rosen; R D Terry; P A Fuld; R Katzman; A Peck
Journal:  Ann Neurol       Date:  1980-05       Impact factor: 10.422

Review 10.  Overview of depression and psychosis in Alzheimer's disease.

Authors:  R E Wragg; D V Jeste
Journal:  Am J Psychiatry       Date:  1989-05       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.